Tandem Diabetes Care (LTS:0M0F) FFO


LTS:0M0F Tandem Diabetes Care Inc LTS:0M0F
67 GF Score
Price $15.87
GF Value $29.23
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Tandem Diabetes Care FFO?

FFO (Funds from operations) only applies to REITs.

LTS:0M0F
67GF Score
Tandem Diabetes Care Inc LTS:0M0F
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Tandem Diabetes Care (LTS:0M0F) Overvalued in 2026?

Based on GuruFocus' analysis, Tandem Diabetes Care stock appears to be undervalued. The current stock price of $15.87 is trading 45.7% below its estimated GF Value™ of $29.23. GuruFocus considers Tandem Diabetes Care to be Possible Value Trap.

Key valuation signals for LTS:0M0F:

  • FFO:
  • GF Value™: $29.23 vs. price of $15.87 (45.7% below fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the LTS:0M0F stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tandem Diabetes Care Business Description

Address 12400 High Bluff Drive, San Diego, CA, USA, 92130
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
67GF Score

Get the complete analysis for LTS:0M0F

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.87
Price
$29.23
GF Value